Fluorophenyl pyrazol compounds

Patent metadata

Field	Value
Publication number	US-9499490-B2
Application number	US-201415037344-A
Country	US
Kind code	B2
Filing date	Dec 11, 2014
Priority date	Dec 19, 2013
Publication date	Nov 22, 2016
Grant date	Nov 22, 2016

Abstract

The present invention provides a compound of the Formula: wherein X is selected from the group consisting of, R is selected from the group consisting of H and CH 3 ; R1 is selected from the group consisting of H, CH 3 , F, Cl, OCH 3 , C(O)OH, C(O)NH 2 or a pharmaceutically acceptable salt thereof.

First claim

What is claimed is:

1. A compound which is

wherein X is selected from the group consisting of

R is selected from the group consisting of H and CH 3 ;
R 1 is selected from the group consisting of H, CH 3 , F, Cl, OCH 3 , C(O)OH, C(O)NH 2 and

or a pharmaceutically acceptable salt thereof.

2. A compound or pharmaceutically acceptable salt thereof, as claimed by claim 1 wherein X is

3. A compound or pharmaceutically acceptable salt thereof, as claimed by claim 1 wherein X is

4. A compound or salt as claimed by claim 3 wherein R 1 is selected from the group consisting of H, F, and CH 3 .

5. A compound or salt as claimed by claim 3 wherein R 1 is

6. A compound as claimed by claim 1 wherein the compound is [3-[[3-(4-Fluorophenyl)-1H-pyrazol-4-yl]oxy]phenyl]methylurea, or a pharmaceutically acceptable salt thereof.

7. A compound or salt as claimed by claim 1 wherein X is

8. A compound or salt as claimed by claim 7 wherein R is CH 3 .

9. A compound as claimed by claim 1 wherein the compound is [6-[[3-(4-Fluorophenyl)-1H-pyrazol-4-yl]oxy]-5-methyl-2-pyridyl]methylurea or a pharmaceutically acceptable salt thereof.

10. A method of providing desired weight loss in a mammal in need thereof, comprising administering an effective amount of a compound as claimed by claim 1 , or a pharmaceutically acceptable salt thereof.

11. A method of treating obesity in a mammal in need thereof, comprising administering an effective amount of a compound as claimed by claim 1 , or a pharmaceutically acceptable salt thereof.

12. A method for providing therapeutic weight loss in a mammal in need thereof, comprising administering an effective amount of a compound as claimed by claim 1 , or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a compound as claimed by claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier, diluent, or excipient.

Assignees

• Lilly Co Eli

Inventors

• Liu Kevin Kun-Chin
• Xie Yinong
• Wu Liang
• Zhou Guoqiang

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title

• A61K31/4152

  having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone · CPC title

• C07D231/18 Primary

  One oxygen or sulfur atom · CPC title